Background: Soluble CD40 ligand (sCD40L) levels are increased during human immunodeficiency virus (HIV) infection, but it is unknown whether monomeric or multimeric forms predominate, and whether there are differential effects of these forms on dendritic cell function and dendritic cell-T cell interactions.
Methods: Immunoblots were performed to delineate various forms of sCD40L present in plasma from HIV-infected donors. Monocyte-derived DCs (moDCs) from seronegative donors were exposed to forms of sCD40L prior to Toll-like receptor (TLR) stimulation and moDC function and T cell function was assessed in vitro. Levels of sCD40L in plasma from ART-treated HIV-infected donors before and after low dose aspirin therapy were measured via ELISA.
Results: Multiple forms of sCD40L were identified in plasma from ART-treated HIV-infected donors, including monomers, dimers, and trimers. Though monomeric and multimeric forms of sCD40L had differential effects on DC activation when given alone, both strongly suppressed secretion of the Th1 skewing cytokine, IL-12, upon subsequent TLR stimulation. Furthermore, moDC exposed to both monomeric and multimeric sCD40L induced T cell anergy and regulatory T cell formation. One week of low dose aspirin decreased sCD40L in ART-treated HIV infected subjects, suggesting that heightened sCD40L is due in part to platelet activation and is responsive to anti-platelet therapy.
Conclusions: Elevated sCD40L during HIV infection contributes to dendritic cell mediated T cell dysfunction. Anti-platelet agents that decrease sCD40L may provide immune modulatory benefits as adjunctive therapies to ART.